M&A / Deals Cytospire hauls in $83M for a new type of T cell engager BioPharma DiveThe British biotechnology startup is making pan-gamma delta T cell engagers it says can address the limitations of similar, existing therapies.OncologyRead full story pharminent May 5, 2026 (Last updated: May 5, 2026) BioPharma Dive The British biotechnology startup is making pan-gamma delta T cell engagers it says can address the limitations of similar, existing therapies. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Amneal Agrees to Acquire Kashiv BioSciences for Total Payment up to $1.1 BillionNext: Autoimmune disease biotech Odyssey sets terms for $225m IPO Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
